XENiOS
XENiOS AG specializes in developing medical devices aimed at treating acute and chronic lung failure, as well as cardiac insufficiency. The company offers a comprehensive range of products, including the iLA active platform for extrapulmonary lung support, iLA Membrane Ventilator for pumpless lung support, and various cannulas and pumps designed for cardiac surgery applications. Additionally, XENiOS provides innovative solutions such as the NovaTherm Heater/Cooler for blood temperature management and the deltastream series for monitoring and managing patient parameters during treatment. The company is uniquely positioned in the market by offering minimally invasive, disposable therapies that address both lung and heart conditions on a single platform, which is not available from other manufacturers. Founded in 2013 and based in Heilbronn, Germany, XENiOS AG also delivers clinical application support, training, and customer service to healthcare providers. As of late 2016, it operates as a subsidiary of Fresenius Medical Care AG & Co. KGaA.
2 past transactions
Xor Labs Toronto
Venture Round in 2016
Xor Labs Toronto is a pioneering company in the field of personalized medicine focused on organ transplantation, specifically targeting lung transplants. The company develops innovative medical devices that enhance the availability of donated lungs for transplantation, addressing the critical needs of patients suffering from severe respiratory diseases such as pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and chronic obstructive pulmonary disease. By advancing the technology associated with lung transplantation, Xor Labs aims to significantly reduce mortality rates among individuals awaiting this life-saving procedure, ultimately transforming the landscape of organ donation and transplantation worldwide.
Xor Labs Toronto
Venture Round in 2016
Xor Labs Toronto is a pioneering company in the field of personalized medicine focused on organ transplantation, specifically targeting lung transplants. The company develops innovative medical devices that enhance the availability of donated lungs for transplantation, addressing the critical needs of patients suffering from severe respiratory diseases such as pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and chronic obstructive pulmonary disease. By advancing the technology associated with lung transplantation, Xor Labs aims to significantly reduce mortality rates among individuals awaiting this life-saving procedure, ultimately transforming the landscape of organ donation and transplantation worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.